Vivozon Pharma Turns Operating Profit Positive in 2Q... "Core Business Turnaround"

Vivozon Pharmaceutical succeeded in turning a profit thanks to the growth of its pharmaceutical business. The company's structure improved as the pharmaceutical business became its main focus following last year's merger.

On the 16th, Vivozon Pharmaceutical announced that its consolidated sales for the second quarter of this year reached 16.6 billion KRW, a 67.7% increase compared to the same period last year. Operating profit turned positive at 800 million KRW.

Prescription drugs (ETC), which account for half of the sales, steadily grew due to the continuous increase in respiratory patients. Chronic disease treatments such as Jebica tablets (hypertension) and Choline Salicylate tablets (cognitive enhancer), along with new products like Daparozin tablets (diabetes), led the improvement in performance.

Additionally, the over-the-counter (OTC) business segment grew by more than 200% in the first half of the year. The fatigue recovery product Laraola liquid signed an exclusive supply contract with Yuhan Corporation in May. From the second half of this year, when full-scale sales and marketing begin, annual sales exceeding 4 billion KRW are expected.

Meanwhile, the contract manufacturing organization (CMO) business also progressed actively, growing by more than 50% compared to the first half of last year. The CMO business recorded sales of over 10 billion KRW in the first half alone.

A company representative stated, “We plan to focus on the pharmaceutical business by divesting from cosmetics, light industry, and healthcare businesses. As the pharmaceutical business continues to grow and the effects of business restructuring take hold, performance improvement will become more evident in the second half of the year.”

Meanwhile, on the 3rd, Vivozon Pharmaceutical applied for preliminary review to the Ministry of Food and Drug Safety for the product approval of the non-narcotic analgesic Opiranzerin injection.

This content was produced with the assistance of AI translation services.